Skip Navigation

Chronic Pancreatitis

printer friendly version

Chronic Pancreatitis. Effects of Pioglitazone on Endocrine Function, Quality of Life, and Exocrine Function & Structure

Study Description

The purpose of this study is to determine if study drug will improve pre-diabetes (insulin resistance) and improve clinical symptoms or laboratory evidence of chronic pancreatitis due to alcohol, the most common cause. The investigators goal is to gather information from this study to help gain understanding of a potential therapy for chronic pancreatitis. The pancreas is a digestive organ that secretes insulin (and other hormones) into the blood for regulating blood sugar (glucose) and digestive enzymes into the intestine for digesting and absorbing nutrients consumed in meals. Chronic pancreatitis is a progressive clinical disease of the pancreas, associated with swelling (inflammation), scarring (fibrosis) and loss of normal functioning tissue. Patients develop diabetes mellitus (elevated blood sugar), malabsorption of nutrients, weight loss and pain. Presently chronic pancreatitis is considered an irreversible condition because the mechanisms responsible for chronic pancreatitis are poorly understood and no therapy is proven. However, recent studies provide important clues that oral medications (Thiazolidinediones) used to treat diabetes mellitus might improve or reverse features of chronic pancreatitis, including elevated sugar or diabetes, reduced secretion of digestive enzymes, and pancreatic swelling and scarring.

Eligibility:

Location of Study Visits: Ann Arbor

Principal Invesitgator: Matthew J DiMagno, MD

Questions or referrals: please contact Michelle Atkinson: (734) 615-6723 or michcast@umich.edu.

Back to top